Jonathan Jay Mazelsky - 08 Aug 2025 Form 4 Insider Report for IDEXX LABORATORIES INC /DE (IDXX)

Reporting relationship: President and CEO, Director
Issuer ticker: IDXX
Reported as of: 08 Aug 2025
Net transaction value: +$109,523
SEC form: 4
Accepted by SEC: 12 Aug 2025, 17:00:15 UTC
Prior SEC filing: 08 Aug 2025
Next SEC filing: 04 Sep 2025
Source filing: View source filing
Reporting owner signature: /s/ Lily J. Lu, Attorney-in-Fact for Jonathan Jay Mazelsky

Key filing fact

Jonathan Jay Mazelsky filed Form 4 for IDEXX LABORATORIES INC /DE (IDXX) on 12 Aug 2025.

Key facts

This page summarizes Jonathan Jay Mazelsky's Form 4 filing for IDEXX LABORATORIES INC /DE (IDXX).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 12 Aug 2025, 17:00.

Change

Previous filing in this sequence was filed on 08 Aug 2025.
Current net transaction value: +$109,523.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001556270 Primary reporting owner

MAZELSKY JONATHAN JAY

Relationship: President and CEO, Director
Address: ONE IDEXX DRIVE, WESTBROOK
Signature: /s/ Lily J. Lu, Attorney-in-Fact for Jonathan Jay Mazelsky
Signature date: 12 Aug 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

IDXX transaction

Common Stock

Options Exercise

Transaction value: $109,523
Shares: +183
Change %: +0.22%
Price: $598.49
Shares after: 83,494
Date: 08 Aug 2025
Ownership: Direct

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

IDXX transaction Derivative

Premium Incentive Stock Option (right-to-buy)

Options Exercise

Transaction value
Shares: -183
Change %: -100%
Price
Shares after: 0
Date: 08 Aug 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 183
Exercise price: $598.49
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Grant of option at a 110% premium to the closing price of Issuer common stock on the Nasdaq Global Select Market on February 12, 2021 to buy shares of Issuer common stock that became exercisable in one installment on February 14, 2025.

Footnote F2

Not applicable.